These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Relation between hyperprolactinemia and polycystic ovary syndrome]. Hámori M; Szendei G; Kovács I; Somos P Zentralbl Gynakol; 1987; 109(8):481-6. PubMed ID: 3111126 [TBL] [Abstract][Full Text] [Related]
4. Prolactin response to thyrotropin-releasing hormone as a guideline for cyclical mastalgia treatment. Rea N; Bove F; Gentile A; Parmeggiani U Minerva Med; 1997 Nov; 88(11):479-87. PubMed ID: 9433398 [TBL] [Abstract][Full Text] [Related]
5. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. Rittmaster RS; Thompson DL J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885 [TBL] [Abstract][Full Text] [Related]
6. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis. Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830 [TBL] [Abstract][Full Text] [Related]
7. Influence of exercise on dehydroepiandrosterone sulphate and delta 4-androstenedione plasma levels in man. Velardo A; Pantaleoni M; Valerio L; Barini A; Marrama P Exp Clin Endocrinol; 1991 Mar; 97(1):99-101. PubMed ID: 1830847 [TBL] [Abstract][Full Text] [Related]
8. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Dunaif A; Mandeli J; Fluhr H; Dobrjansky A J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783 [TBL] [Abstract][Full Text] [Related]
9. Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome. Wortsman J; Hirschowitz JS Obstet Gynecol; 1980 Apr; 55(4):460-3. PubMed ID: 6768040 [TBL] [Abstract][Full Text] [Related]
10. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. Carmina E; Rosato F; Maggiore M; Gagliano AM; Indovina D; Jannì A Acta Endocrinol (Copenh); 1984 Jan; 105(1):99-104. PubMed ID: 6229966 [TBL] [Abstract][Full Text] [Related]
12. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity. Corenblum B; Taylor PJ Fertil Steril; 1982 Nov; 38(5):549-52. PubMed ID: 6813147 [TBL] [Abstract][Full Text] [Related]
13. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688 [TBL] [Abstract][Full Text] [Related]
14. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Kazerooni T; Dehghan-Kooshkghazi M Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019 [TBL] [Abstract][Full Text] [Related]
15. [Relation between prolactin and dehydroepiandrosterone sulfate in women with polycystic ovary disease]. Bruno B; Poccia G; Masci A Minerva Endocrinol; 1985; 10(4):223-7. PubMed ID: 2939335 [No Abstract] [Full Text] [Related]